Zacks Small-Cap Research

NSMC therapy subscription business was a good move. So, while tomo sales have been disappointing, with PMA approval of 2.0 anticipated any day now, we continue to think revenue and the rest of the income statement show dramatic improvement next year. And in the meantime, with the boat anchor cut loose, expense base trimmed and incremental ................
................